Arix Bioscience
20 Berkeley Square
London
W1J 6EQ
United Kingdom
Tel: 44-0-20-7290-1050
Website: https://arixbioscience.com/
Email: info@arixbioscience.com
About Arix Bioscience
Arix Bioscience is a healthcare and life science company that drives value in private and public companies through operational and strategic support and direction as well as patient capital.The creation of renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has offices in New York.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Dr. Joe Anderson
Chairman: Jonathan Peacock
Deputy Chairman: Professor Sir Christopher Evans
CFO: James Rawlingson
25 articles about Arix Bioscience
-
Arix announces strategic and operational update
6/8/2020
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company investing in and building breakthrough biotech companies, today announces that Christian Schetter, PhD, currently Entrepreneur in Residence at Arix, has been appointed as a Managing Director.
-
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
1/27/2020
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.
-
Arix Bioscience plc: Annual Results for the year ended 31 December 2018
3/28/2019
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences, today announces its annual results for the year ended 31 December 2018.
-
Arix Bioscience plc Notice of Results
3/21/2019
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its annual results for the period ended 31 December 2018 on Thursday, 28 March 2019.
-
Arix co-leads $63 million Series B investment round for Imara
3/18/2019
Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
Arix Bioscience announces Management and Board changes Joe Anderson appointed as CEO
2/19/2019
Arix Bioscience plc (LSE:ARIX) ("Arix" or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, has been reappointed as Chief Executive Officer and will re-join the Arix Board.
-
Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)
12/11/2018
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today announces the appointment of Dr Christian Schetter as Entrepreneur in Residence (EIR)
-
Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound
11/15/2018
Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
-
Arix Bioscience plc Co-leads $58 million Series A investment round for VelosBio
10/1/2018
Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies
-
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
-
Movers and Shakers for Sept. 17
9/17/2018
Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week. -
Arix Bioscience appoints Arthur Pappas to the Board of Directors
9/14/2018
Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.
-
Arix Bioscience plc: Changes announced to executive team to accelerate growth and strategy
9/12/2018
Changes announced to executive team to accelerate growth and strategy
-
Arix Bioscience announces first VIPE investment
8/6/2018
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
-
Evotec Forms Academic Bridge 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center
5/31/2018
Initial term of LAB591 is five years.
-
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies
2/21/2018
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialize Innovative Therapies
-
Arix Bioscience Co-Leads $29 Million Series A Financing For Precithera
7/27/2017
-
Arix Bioscience Leads $45 Million Series B Financing Round Into LogicBio
6/28/2017
-
Arix Bioscience Participates In $20 Million Fundraise For Mitoconix Bio
6/27/2017